KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma (KPT-330+RICE)
A Phase I Investigator-Initiated Study of Selinexor (KPT-330) Plus RICE in Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
Sponsor: FDA Office of Orphan Products Development
A PHASE1 clinical study on Diffuse Large B-Cell Lymphoma, this trial is completed. The trial is conducted by FDA Office of Orphan Products Development and has accumulated 14 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
14 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
May 2022 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Oct 2021 — May 2022 [monthly]
Active Not Recruiting PHASE1
-
Sep 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE1
▶ Show 9 earlier versions
-
Apr 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE1
-
Jan 2021 — Apr 2021 [monthly]
Active Not Recruiting PHASE1
-
May 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Feb 2020 — May 2020 [monthly]
Recruiting PHASE1
-
Feb 2019 — Feb 2020 [monthly]
Recruiting PHASE1
-
Jun 2018 — Feb 2019 [monthly]
Recruiting PHASE1
-
May 2017 — Jun 2018 [monthly]
Recruiting PHASE1
-
Feb 2017 — May 2017 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Dec 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- FDA Office of Orphan Products Development
- Karyopharm Therapeutics Inc
- The Leukemia and Lymphoma Society
- Weill Medical College of Cornell University
For direct contact, visit the study record on ClinicalTrials.gov .